5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 10.36▲ | 10.24▲ | 10.16▲ | 9.83▲ | 9.12▲ |
MA10 | 10.33▲ | 10.08▲ | 9.96▲ | 9.52▲ | 9.23▲ |
MA20 | 10.25▲ | 9.89▲ | 9.77▲ | 9.02▲ | 9.31▲ |
MA50 | 10.07▲ | 9.74▲ | 9.63▲ | 9.18▲ | 8.97▲ |
MA100 | 9.90▲ | 9.59▲ | 9.15▲ | 9.33▲ | 9.33▲ |
MA200 | 9.76▲ | 9.08▲ | 9.03▲ | 9.02▲ | 9.67▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.004▲ | 0.057▲ | 0.070▲ | 0.162▲ | 0.042▲ |
RSI | 78.616▲ | 86.231▲ | 83.393▲ | 72.546▲ | 60.787▲ |
STOCH | 86.208▲ | 93.928▲ | 97.046▲ | 94.683▲ | 44.263 |
WILL %R | -8.696▲ | -2.667▲ | -2.051▲ | -1.327▲ | -2.734▲ |
CCI | 148.272▲ | 156.395▲ | 159.255▲ | 136.039▲ | 169.531▲ |
Monday, April 28, 2025 07:37 AM
Investing.com - Theravance Biopharma (NASDAQ: TBPH) reported fourth quarter EPS of $-0.31, $0.11 worse than the analyst estimate... ByInvesting.com • Feb 26, 2025 H.C. Wainwright maintains ...
|
Monday, April 28, 2025 05:34 AM
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be ...
|
Friday, April 18, 2025 02:30 AM
Short interest in Theravance Biopharma Inc (NASDAQ:TBPH) decreased during the last reporting period, falling from 3.66M to 3.57M. This put 14.09% of the company's publicly available shares short.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 9.85 | 10.42 | 9.74 | 10.39 | 424,596 |
30/04/25 | 9.49 | 9.8062 | 9.45 | 9.77 | 239,693 |
29/04/25 | 9.70 | 9.74 | 9.49 | 9.495 | 187,722 |
28/04/25 | 9.79 | 9.80 | 9.62 | 9.75 | 187,457 |
25/04/25 | 9.50 | 9.75 | 9.415 | 9.75 | 215,186 |
24/04/25 | 9.43 | 9.56 | 9.33 | 9.54 | 258,760 |
23/04/25 | 9.43 | 9.51 | 9.30 | 9.45 | 184,153 |
22/04/25 | 9.19 | 9.36 | 9.12 | 9.31 | 217,628 |
21/04/25 | 8.56 | 9.18 | 8.52 | 9.13 | 304,436 |
17/04/25 | 8.58 | 8.69 | 8.51 | 8.62 | 160,020 |
|
|
||||
|
|
||||
|
|